Brand name · Levonorgestrel
Plan B One-Step: adverse event reports filed with FDA
35,324 reports list it as a suspect or interacting product, 2009–2026. Class: Progestin.
- 35,324
- reports as suspect product
- 0.2% of all reports · about 2,110 a year
- 327
- reports, 12 months to June 2026
- 325 in the 12 months before
- 4.9%
- marked serious by the reporter
- 41.9% across the class
- 0%
- record death among outcomes, as reported
- 3 reports · not verified by FDA
Between October 2009 and June 2026, 35,324 adverse event reports received by FDA list the brand name Plan B One-Step (levonorgestrel) as a suspect or interacting product. Reports that mention it only as a concomitant medication (5) are left out of every figure here.
In the 12 months to June 2026, 327 reports listed it, close to the 325 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 2,110 reports a year and 0.2% of the 20,646,523 reports in the database, and 12% of the reports for the progestin class. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded menstruation irregular (37.3%), vaginal haemorrhage (19%) and menstruation delayed (12.4%). A report can list several reactions, so shares add to more than 100%; 393 different terms appear across these reports. Menstruation irregular is recorded in 37.3% of these reports, a larger share than in the median progestin drug (0.9%).
4.9% of the reports are marked serious by the reporter (41.9% across the class); 0% record death among the outcomes and 0% record hospitalisation, as reported. 90.5% of the reports came from consumers, and the largest patient age group is 18 to 44 (35.9%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Plan B One-Step reports recording the termmedian drug in progestin
- Menstruation irregularirregular periods37.3%13,189
- Vaginal haemorrhagevaginal bleeding19%6,695
- Menstruation delayed12.4%4,374
- Nauseafeeling sick12.1%4,257
- Dysmenorrhoea9.4%3,328
- Vomitingbeing sick8%2,823
- Pelvic pain6.2%2,178
- Headachehead pain5.4%1,923
- Fatiguetiredness4.9%1,730
- Pregnancy after post coital contraception4.9%1,715
- Dizzinesslight-headedness or unsteadiness4.4%1,568
- Breast tenderness4.1%1,460
- Vaginal discharge4.1%1,444
- Abdominal painstomach or belly pain3.9%1,392
- Drug ineffectivethe medicine did not work as expected3.7%1,319
- Intentional product misusedeliberate use not as intended2.7%970
- Back painback pain2.7%964
- Abdominal distensiona bloated abdomen2.7%959
- Abdominal pain upperupper stomach pain2.5%884
- Metrorrhagia2.3%830
- Menorrhagiaheavy periods2.2%793
- Breast painbreast pain1.9%684
- Muscle spasmsmuscle cramps1.9%684
- Abdominal pain lower1.8%619
- Diarrhoealoose or frequent stools1.7%608
- Abdominal discomfortstomach discomfort1%357
- Product use in unapproved indicationused for a purpose not on the label0.9%305
- Menstrual disorder0.8%283
- Pollakiuriapassing urine more often0.6%225
Top 30 of 393 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 17 drugs in the progestin class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 293,492 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 99.8% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Post coital contraception | 32,878 | 93.1% |
| Contraception | 134 | 0.4% |
| Menstruation irregular | 52 | 0.1% |
| Abortion induced | 18 | 0.1% |
| Product use in unapproved indication | 10 | 0% |
| Menstrual cycle management | 7 | 0% |
The indication field is filled in by the reporter and is often blank; shares are of all 35,324 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Plan B One-Step reports |
|---|---|---|
| Zoloft | 126 | 0.4% |
| Vitamin d | 121 | 0.3% |
| Xanax | 113 | 0.3% |
| Zyrtec | 113 | 0.3% |
| Adderall | 110 | 0.3% |
| Synthroid | 109 | 0.3% |
| Iron | 102 | 0.3% |
| Lexapro | 102 | 0.3% |
| Ibuprofen | 88 | 0.2% |
| Albuterol | 85 | 0.2% |
Other products listed in reports where Plan B One-Step is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Plan B One-Step | Progestin | All reports |
|---|---|---|---|
| Reports as suspect product | 35,324 | 293,492 | 20,646,523 |
| Share of that pool | — | 12% | 0.2% |
| Reports, latest 12 months | 327 | — | 1,332,454 |
| Marked serious | 4.9% | 41.9% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 0 | 4 | 91 |
| Hospitalisation recorded, per 1,000 reports | 0 | 52 | 213 |
| Consumer-filed share | 90.5% | 46.4% | 45.8% |
| Top term, share of reports | Menstruation irregular 37.3% | median 0.9% | 0.1% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the progestin class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Mirena | brand | 129,479 | 3,433 | 40.6% |
| Nexplanon | brand | 43,751 | 836 | 24.8% |
| Provera | brand | 20,400 | 26 | 98.6% |
| Depo-Provera | brand | 18,669 | 11,383 | 87.1% |
| Liletta | brand | 10,567 | 850 | 8.2% |
| Medroxyprogesterone acetate | generic | 8,621 | 818 | 89% |
| Kyleena | brand | 8,075 | 694 | 40.4% |
| Skyla | brand | 5,310 | 125 | 41.7% |
| Medroxyprogesterone | generic | 3,030 | 165 | 73.8% |
| Levonorgestrel | generic | 2,711 | 219 | 72.2% |
| Take Action | brand | 2,550 | 20 | 8.1% |
| Etonogestrel | generic | 2,112 | 255 | 89.7% |
| Aftera | brand | 818 | 19 | 5% |
| Norethindrone | generic | 797 | 52 | 52.1% |
| Norethindrone acetate | generic | 722 | 8 | 35.9% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Plan B One-Step reports
How many adverse event reports has FDA received for Plan B One-Step?
35,324 reports list Plan B One-Step as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 327 of them arrived in the latest 12 months. Another 5 list it only as a concomitant medication.
What reactions are recorded in Plan B One-Step reports?
menstruation irregular (37.3%), vaginal haemorrhage (19%), menstruation delayed (12.4%), nausea (12.1%) and dysmenorrhoea (9.4%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Plan B One-Step was responsible.
How serious are the reports?
4.9% are marked serious by the reporter. Among the outcomes recorded, 0% of reports include death and 0% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (90.5%), not given (9.1%) and other health professional (0.3%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Plan B One-Step rising?
327 reports in the 12 months to June 2026, close to the 325 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Plan B One-Step was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Plan B One-Step?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Plan B One-Step as a suspect or interacting product; reports listing it only as a concomitant medication (5) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.